Endoplasmic Reticulum Stress Protein & Emerging Oncology Target. High-fidelity reagents for secreted AGR2 targeting, ADC development, and redox-state dependent binding assays in pancreatic and prostate cancer models.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for AGR2/AG-2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AGR2 Recombinant Protein Full-length mature protein (18-20 kDa), Thioredoxin domain (CXXC) intact, HEK293 expressed for native disulfide formation. High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. |
View AGR2 Products |
| Gene Delivery | AGR2 Lentivirus Particles Native ORF with secretion signal peptide for stable secretory cell line construction. High titer (>10^8 TU/ml). |
View AGR2 Products |
| Benchmark Ab | Anti-AGR2 Antibody (Recombinant) Sequence-optimized positive control for ELISA/IHC validation. Endotoxin controlled. |
View AGR2 Products |
| Validator | AGR2 siRNA Set (3 unique sequences) For knockdown verification in secretory assays. Sequence-verified targets. |
View AGR2 Products |
| Homolog Target | AGR3 (Anterior Gradient 3) Secreted homolog with 71% identity; potential cross-reactivity counter-screening. |
View AGR3 Products |
| Functional Partner | PDIA4 (Protein Disulfide Isomerase) ER resident interacting partner; co-target for folding pathway inhibition. |
View PDIA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Redox-sensitive Conformational Epitopes | HEK293 expressed protein maintains native disulfide bonds (CXXC motif); proper thioredoxin folding essential for antibody recognition. |
| Secreted vs. Intracellular Detection | Matched pair: Recombinant protein standard + Lentivirus-stable cell lines for sandwich ELISA development. |
| Cross-species Preclinical Translation | Human/Mouse/Cyno AGR2 ortholog proteins available with >90% sequence homology verification. |
| Off-target Homolog Risk (AGR3) | Homolog panel proteins (AGR2/AGR3) strictly verified by mass spec for selectivity screening. |
| Aggregation in High-concentration Formulations | Low-endotoxin (<1EU/µg) protein reduces aggregation risk in ADC conjugation reactions. |
Live AGR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AGR2 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic agents to Antibody-Drug Conjugates (ADCs) targeting secreted AGR2 in the tumor microenvironment. As first-generation ADCs enter Phase I, the next wave of R&D is targeting combination strategies with ER stress inducers and redox pathway modulators to maximize therapeutic index in pancreatic ductal adenocarcinoma (PDAC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging biotechs (PDAC-focused) | Pancreatic Cancer, Prostate Cancer | Internalization Assay (Need high-purity AGR2 with intact secretion signal conformation) |
| Neutralizing mAb | Preclinical academic consortia | Solid Tumors (AGR2-high) | Epitope Mapping (Need Redox-state controlled antigen for CXXC domain accessibility) |
| Small Molecule (Thioredoxin inhibitor) | Early discovery programs | Metastatic Cancer | Enzymatic Activity Assay (Need functionally folded recombinant protein) |
| PROTAC (Intracellular) | Novel degradation platforms | ER-resident Pool Targeting | Cell Permeability/Localization (Need lentivirus-based stable cell lines with ER reporters) |